Rijksinstituut voor VolksgezondheidAn early dialogue between nanomedicine developers and regulatory authorities are of utmost importance to anticipate quality and safety requirements for these innovative health products. In order to stimulate interactions between the various communities involved in a translation of nanomedicines to clinical applications, the European Commission's Joint Research Centre hosted a workshop titled “Bridging communities in the field of Nanomedicine” in Ispra/Italy on the 27th −28th September 2017. Experts from regulatory bodies, research institutions and industry came together to discuss the next generation of nanomedicines and their needs to obtain regulatory approval. The workshop participants came up with recommendations highlighting methodological gaps that should be addressed in ongoing projects addressing the regulatory science of nanomedicines. In addition, individual opinions of experts relevant to progress of the regulatory science in the field of nanomedicine were summarised in the format of a survey.
Technologische ontwikkelingen maken het mogelijk om materialen met hele kleine afmetingen te maken, te veranderen of te gebruiken. We noemen dat nanotechnologie. De nanomaterialen die producenten hiermee maken hebben interessante nieuwe eigenschappen. Zo worden niet-geleidende stoffen bijvoorbeeld geleidend, of ondoorzichtige materialen doorzichtig. Dat komt doordat nanodeeltjes waaruit de nanomaterialen bestaan, zich anders gedragen en anders reageren op hun omgeving.
Nanotechnology has multiple applications. However, there is still much uncertainty about the potential risks related to this new technology. To help resolve these uncertainties, RIVM conducts research and provides policy advice to various Dutch ministries.